HLA Fully-Mismatched Sibling-Derived CD7 CAR-T Therapy Bridging to Haploidentical Hematopoietic Stem Cell Transplantation for Hepatosplenic γδ T-cell Lymphoma
While chimeric antigen receptor (CAR)-T-cell therapy has demonstrated remarkable effectiveness in the treatment of B-cell lymphomas and leukemias, research on T-cell malignancies is still limited. Here, we reported a patient with hepatosplenic γδ T-cell lymphoma refractory to multiple lines of chemo...
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2023-09-01
|
| Series: | Cell Transplantation |
| Online Access: | https://doi.org/10.1177/09636897231194265 |
| _version_ | 1797692201741844480 |
|---|---|
| author | Xueer Xu Cheng Zu Mingming Zhang Pingnan Xiao Ruimin Hong Jingjing Feng Huijun Xu Jiazhen Cui Jian Yu Jimin Shi Guoqing Wei Alex H. Chang He Huang Yongxian Hu |
| author_facet | Xueer Xu Cheng Zu Mingming Zhang Pingnan Xiao Ruimin Hong Jingjing Feng Huijun Xu Jiazhen Cui Jian Yu Jimin Shi Guoqing Wei Alex H. Chang He Huang Yongxian Hu |
| author_sort | Xueer Xu |
| collection | DOAJ |
| description | While chimeric antigen receptor (CAR)-T-cell therapy has demonstrated remarkable effectiveness in the treatment of B-cell lymphomas and leukemias, research on T-cell malignancies is still limited. Here, we reported a patient with hepatosplenic γδ T-cell lymphoma refractory to multiple lines of chemotherapy, who eventually achieved first complete remission with flow cytometry-confirmed minimal residual disease negativity after human leukocyte antigen (HLA) fully-mismatched sibling-derived CD7 CAR-T therapy. However, given the allogeneic nature, CAR-T cells dropped rapidly after a peak of 83.4% of circulating T-cells. Cytokine release syndrome, cytopenia, and infections occurred but were manageable after treatments. After the consolidative haploidentical hematopoietic stem cell transplantation (HSCT), the patient remained in remission at the end of the follow-up (13 months post-CAR-T infusion). This is the first case of relapsed/refractory hepatosplenic γδ T-cell lymphoma who achieved lasting CR after HLA fully-mismatched sibling-derived CD7 CAR-T therapy bridging to haploidentical HSCT. |
| first_indexed | 2024-03-12T02:24:11Z |
| format | Article |
| id | doaj.art-89ed10010d0b4e5c94425e704efa0336 |
| institution | Directory Open Access Journal |
| issn | 1555-3892 |
| language | English |
| last_indexed | 2024-03-12T02:24:11Z |
| publishDate | 2023-09-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Cell Transplantation |
| spelling | doaj.art-89ed10010d0b4e5c94425e704efa03362023-09-05T22:33:23ZengSAGE PublishingCell Transplantation1555-38922023-09-013210.1177/09636897231194265HLA Fully-Mismatched Sibling-Derived CD7 CAR-T Therapy Bridging to Haploidentical Hematopoietic Stem Cell Transplantation for Hepatosplenic γδ T-cell LymphomaXueer Xu0Cheng Zu1Mingming Zhang2Pingnan Xiao3Ruimin Hong4Jingjing Feng5Huijun Xu6Jiazhen Cui7Jian Yu8Jimin Shi9Guoqing Wei10Alex H. Chang11He Huang12Yongxian Hu13Zhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy, Hangzhou, ChinaZhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy, Hangzhou, ChinaZhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy, Hangzhou, ChinaZhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy, Hangzhou, ChinaZhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy, Hangzhou, ChinaZhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy, Hangzhou, ChinaZhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy, Hangzhou, ChinaZhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy, Hangzhou, ChinaZhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy, Hangzhou, ChinaZhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy, Hangzhou, ChinaZhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy, Hangzhou, ChinaClinical Translational Research Center, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, ChinaZhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy, Hangzhou, ChinaZhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy, Hangzhou, ChinaWhile chimeric antigen receptor (CAR)-T-cell therapy has demonstrated remarkable effectiveness in the treatment of B-cell lymphomas and leukemias, research on T-cell malignancies is still limited. Here, we reported a patient with hepatosplenic γδ T-cell lymphoma refractory to multiple lines of chemotherapy, who eventually achieved first complete remission with flow cytometry-confirmed minimal residual disease negativity after human leukocyte antigen (HLA) fully-mismatched sibling-derived CD7 CAR-T therapy. However, given the allogeneic nature, CAR-T cells dropped rapidly after a peak of 83.4% of circulating T-cells. Cytokine release syndrome, cytopenia, and infections occurred but were manageable after treatments. After the consolidative haploidentical hematopoietic stem cell transplantation (HSCT), the patient remained in remission at the end of the follow-up (13 months post-CAR-T infusion). This is the first case of relapsed/refractory hepatosplenic γδ T-cell lymphoma who achieved lasting CR after HLA fully-mismatched sibling-derived CD7 CAR-T therapy bridging to haploidentical HSCT.https://doi.org/10.1177/09636897231194265 |
| spellingShingle | Xueer Xu Cheng Zu Mingming Zhang Pingnan Xiao Ruimin Hong Jingjing Feng Huijun Xu Jiazhen Cui Jian Yu Jimin Shi Guoqing Wei Alex H. Chang He Huang Yongxian Hu HLA Fully-Mismatched Sibling-Derived CD7 CAR-T Therapy Bridging to Haploidentical Hematopoietic Stem Cell Transplantation for Hepatosplenic γδ T-cell Lymphoma Cell Transplantation |
| title | HLA Fully-Mismatched Sibling-Derived CD7 CAR-T Therapy Bridging to Haploidentical Hematopoietic Stem Cell Transplantation for Hepatosplenic γδ T-cell Lymphoma |
| title_full | HLA Fully-Mismatched Sibling-Derived CD7 CAR-T Therapy Bridging to Haploidentical Hematopoietic Stem Cell Transplantation for Hepatosplenic γδ T-cell Lymphoma |
| title_fullStr | HLA Fully-Mismatched Sibling-Derived CD7 CAR-T Therapy Bridging to Haploidentical Hematopoietic Stem Cell Transplantation for Hepatosplenic γδ T-cell Lymphoma |
| title_full_unstemmed | HLA Fully-Mismatched Sibling-Derived CD7 CAR-T Therapy Bridging to Haploidentical Hematopoietic Stem Cell Transplantation for Hepatosplenic γδ T-cell Lymphoma |
| title_short | HLA Fully-Mismatched Sibling-Derived CD7 CAR-T Therapy Bridging to Haploidentical Hematopoietic Stem Cell Transplantation for Hepatosplenic γδ T-cell Lymphoma |
| title_sort | hla fully mismatched sibling derived cd7 car t therapy bridging to haploidentical hematopoietic stem cell transplantation for hepatosplenic γδ t cell lymphoma |
| url | https://doi.org/10.1177/09636897231194265 |
| work_keys_str_mv | AT xueerxu hlafullymismatchedsiblingderivedcd7carttherapybridgingtohaploidenticalhematopoieticstemcelltransplantationforhepatosplenicgdtcelllymphoma AT chengzu hlafullymismatchedsiblingderivedcd7carttherapybridgingtohaploidenticalhematopoieticstemcelltransplantationforhepatosplenicgdtcelllymphoma AT mingmingzhang hlafullymismatchedsiblingderivedcd7carttherapybridgingtohaploidenticalhematopoieticstemcelltransplantationforhepatosplenicgdtcelllymphoma AT pingnanxiao hlafullymismatchedsiblingderivedcd7carttherapybridgingtohaploidenticalhematopoieticstemcelltransplantationforhepatosplenicgdtcelllymphoma AT ruiminhong hlafullymismatchedsiblingderivedcd7carttherapybridgingtohaploidenticalhematopoieticstemcelltransplantationforhepatosplenicgdtcelllymphoma AT jingjingfeng hlafullymismatchedsiblingderivedcd7carttherapybridgingtohaploidenticalhematopoieticstemcelltransplantationforhepatosplenicgdtcelllymphoma AT huijunxu hlafullymismatchedsiblingderivedcd7carttherapybridgingtohaploidenticalhematopoieticstemcelltransplantationforhepatosplenicgdtcelllymphoma AT jiazhencui hlafullymismatchedsiblingderivedcd7carttherapybridgingtohaploidenticalhematopoieticstemcelltransplantationforhepatosplenicgdtcelllymphoma AT jianyu hlafullymismatchedsiblingderivedcd7carttherapybridgingtohaploidenticalhematopoieticstemcelltransplantationforhepatosplenicgdtcelllymphoma AT jiminshi hlafullymismatchedsiblingderivedcd7carttherapybridgingtohaploidenticalhematopoieticstemcelltransplantationforhepatosplenicgdtcelllymphoma AT guoqingwei hlafullymismatchedsiblingderivedcd7carttherapybridgingtohaploidenticalhematopoieticstemcelltransplantationforhepatosplenicgdtcelllymphoma AT alexhchang hlafullymismatchedsiblingderivedcd7carttherapybridgingtohaploidenticalhematopoieticstemcelltransplantationforhepatosplenicgdtcelllymphoma AT hehuang hlafullymismatchedsiblingderivedcd7carttherapybridgingtohaploidenticalhematopoieticstemcelltransplantationforhepatosplenicgdtcelllymphoma AT yongxianhu hlafullymismatchedsiblingderivedcd7carttherapybridgingtohaploidenticalhematopoieticstemcelltransplantationforhepatosplenicgdtcelllymphoma |